NCT06772220 Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease
| NCT ID | NCT06772220 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oregon Health and Science University |
| Condition | Parkinson&Amp;#39;s Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-03-05 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-03-05 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria. 2. Currently treated with levodopa at a minimum dose of 300 mg/day 3. Montreal Cognitive Assessment (MOCA) ≥15 4. Demonstrated capacity to provide informed consent. 5. 40-90 years of age 6. Estimated glomerular filtration rate ≥60 7. Absence of uncontrolled hypertension in medical history 8. Absence of insulin use Exclusion Criteria: \-
Contact & Investigator
Joseph Quinn, MD
PRINCIPAL INVESTIGATOR
Oregon Health & Science University (OHSU)
Frequently Asked Questions
Who can join the NCT06772220 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 90 Years, studying Parkinson&Amp;#39;s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06772220 currently recruiting?
Yes, NCT06772220 is actively recruiting participants. Contact the research team at PDResearch@ohsu.edu for enrollment information.
Where is the NCT06772220 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT06772220 clinical trial?
NCT06772220 is sponsored by Oregon Health and Science University. The principal investigator is Joseph Quinn, MD at Oregon Health & Science University (OHSU). The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.